Acomplia Aventis Rimonabant Sanofi

Worldwide Shipping Pharmacy

Acomplia Aventis Rimonabant Sanofi

Rimonabant's versatility acomplia aventis rimonabant sanofi traces back to its effects on the brain's reward system, circuitry that tells you to keep on doing something. Pleasurable things like drinking alcohol Acomplia aventis rimonabant sanofi are thought to activate a feeling of reward by acting through the endocannabinoid system. The results were broadly in line with our expectations. The French company named acomplia aventis rimonabant sanofi its U.
We are 99. 9 per cent sure of approval, a Sanofi spokesman said. That burnished the drug's reputation after two studies in March, which suggested it could fight both obesity and smoking, two of humanity's biggest killers. The indications for which it is approved are also important. Other recent studies suggest that rimonabant might acomplia aventis rimonabant sanofi break addictions to nicotine, alcohol, and certain other drugs. As for health-threatening side effects of the drug, "there don't seem to be any red flags acomplia aventis rimonabant sanofi coming up over 2 years,' said Pi-Sunyer. The drug, which Paris-based manufacturer Sanofi-Aventis calls Acomplia, blocks cells' receptors for chemicals called cannabinoids, which include substances in marijuana.
"We should be encouraged that the drug appears safe at 2 years and effective" at maintaining weight loss. The company expects to file for FDA approval by the end of the year. Side effects such as depression, anxiety, and nausea accounted for a small minority of dropouts in both the drug and placebo groups. However, we acomplia aventis rimonabant sanofi believe regulatory uncertainties will remain. It is the first of a new generation of drugs set to hit the market in the next few years that could transform obesity, still a small market, into a gold mine for the pharmaceutical industry. The expected green light from Brussels in the next few weeks would mean that the acomplia aventis rimonabant sanofi french giant Sanofi-Aventis could begin marketing the treatment, called rimonabant but branded as Acomplia, later this summer.

 
Comments (7)
  • hiroki | Monday 30th November 2009 09:19:23 AM

    George Kunos of acomplia aventis rimonabant sanofi the institute.


  • kaya | Wednesday 2nd December 2009 02:24:23 AM

    It's not being obese that kills you, it's the side-effects that come along with it, said Dr Julian Mercer of the Rowett Institute.


  • laba | Sunday 22nd November 2009 09:20:13 AM

    Alimera Sciences, an ophthalmic pharmaceutical company, said the FDA approved an Rx-to-OTC switch new acomplia aventis rimonabant sanofi drug application for its ophthalmic solution Alaway (ketotifen fumarate ophthalmic solution 0.


  • bahraini | Monday 30th November 2009 02:42:49 AM

    It has a path to revenues that we rarely ever see from a pharma product.

    The treatment is the first in a new class of drugs called cannabinoid CB-1 blockers, which suppress appetite by blocking the receptor in the brain responsible for hunger pangs, which can be stimulated by marijuana.


  • steven | Monday 30th November 2009 06:13:07 AM

    Only 37 and 33 percent acomplia aventis rimonabant sanofi of volunteers getting lower-dose rimonabant and placebo, respectively, achieved comparable weight loss.


  • montazemi | Friday 20th November 2009 12:03:02 AM

    Neither can be prescribed for any indications beyond weight loss.